SCHEMBL3751656

SCHEMBL3751656

CC1(C)CC(=O)c2sc(N3CCOCC3)c(-c3ccnc(-c4cccc(C(=O)NCC5CCNCC5)c4)c3)c2C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.40
FLT3 P36888 4/20 0.39
KDM1A O60341 1/20 0.38
HDAC1 Q13547 1/20 0.38
MAPK13 O15264 1/20 0.37
HSPB1 P04792 1/20 0.37
MAPK12 P53778 1/20 0.37
MAPK11 Q15759 1/20 0.37
MAPK14 Q16539 1/20 0.37
JAK2 O60674 1/20 0.37
LMNA P02545 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
ALDH1A1 P00352 1/20 0.36
POLB P06746 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ACACB O00763 1/20 0.36
ACACA Q13085 1/20 0.36
PARP1 P09874 1/20 0.36
TYRO3 Q06418 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3759237 0.91 KDM1A (0.38) KDM1AHDAC1MAPK13HSPB1MAPK12
SCHEMBL3756615 0.87 ATR (0.38) FLT3KDM1AHDAC1MAPK14JAK2
SCHEMBL3764901 0.86 PIK3CA (0.41) KDM1AHDAC1JAK2SCN9ABUB1
SCHEMBL3762510 0.85 PRKD1 (0.41) KDM1AHDAC1JAK2MAP4K4
SCHEMBL3761528 0.85 PLK4 (0.38) FLT3JAK2HPGDMAP4K4BUB1
SCHEMBL3760088 0.84 KDM1A (0.40) KDM1AHDAC1JAK2POLBSCN9A
SCHEMBL3762181 0.84 PIK3R1 (0.37) JAK2TYRO3BUB1
SCHEMBL3760081 0.84 SCN9A (0.38) KDM1AHDAC1JAK2SCN9ABUB1
SCHEMBL3761577 0.83 PRKDC (0.42) KDM1AHDAC1LMNAALDH1A1SCN9A
SCHEMBL3762759 0.83 PRKDC (0.40) KDM1AHDAC1LMNAALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA PIM1 389/4885FLT3 549/4885KDM1A 3543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.